古塞奇尤单抗、依奇珠单抗、司库奇尤单抗、乌司奴单抗和阿达木单抗治疗银屑病患者的药物生存率及其与疗效和安全性的关联
这项前瞻性队列研究基于英国和爱尔兰BADBIR登记数据(2007年11月至2021年8月),纳入16122个治疗疗程,评估五种生物制剂治疗银屑病的药物生存率。结果显示,在疗效相关生存率方面,古塞奇尤单抗最高(调整HR 0.13),阿达木单抗最低(调整HR 2.37);安全性方面,阿达木单抗和依奇珠单抗生存率低于乌司奴单抗。银屑病关节炎、既往生物制剂暴露、甲受累和 ethnicity 是疗效相关生存率的效应修饰因素。
要点
- 古塞奇尤单抗疗效相关药物生存率最高,阿达木单抗最低。
- 安全性相关生存率:阿达木单抗和依奇珠单抗低于乌司奴单抗。
- 银屑病关节炎、既往生物制剂暴露、甲受累和 ethnicity 是疗效相关生存率的效应修饰因素。
核心结论
- 该队列研究结果提示,在BADBIR纳入的生物制剂中,古塞奇尤单抗的疗效相关治疗持续性药物生存率最高。
- 除乌司奴单抗外,古塞奇尤单抗的安全性相关药物生存率高于其他生物制剂。
- 银屑病关节炎、甲受累、既往生物制剂暴露和 ethnicity 是生物制剂疗效相关生存率的效应修饰因素。
- 这些关于长期治疗持续性、安全性和耐受性的信息可能有助于患者及其临床医生做出启动生物制剂治疗的知情决策。
研究设计与样本
- 前瞻性队列研究,使用英国和爱尔兰皮肤科医师生物制剂和免疫调节剂登记(BADBIR)2007年11月至2021年8月的数据。
- 纳入16122个治疗疗程:阿达木单抗6607个(41.0%)、乌司奴单抗5405个(33.5%)、司库奇尤单抗2677个(16.6%)、古塞奇尤单抗730个(4.5%)、依奇珠单抗703个(4.4%)。
- 采用生存分析,并分别为疗效和安全性相关的药物生存率拟合灵活的 parametric 模型。
主要发现
- 疗效相关第1年粗生存函数:阿达木单抗0.81(95%CI 0.80-0.82),乌司奴单抗0.89(95%CI 0.88-0.89),司库奇尤单抗0.86(95%CI 0.85-0.87),古塞奇尤单抗0.94(95%CI 0.92-0.96),依奇珠单抗0.86(95%CI 0.83-0.89)。
- 疗效多变量模型调整生存曲线显示,与乌司奴单抗相比,古塞奇尤单抗生存率更高(调整HR 0.13,95%CI 0.03-0.56),阿达木单抗生存率更低(调整HR 2.37,95%CI 2.03-2.76)。
- 司库奇尤单抗和依奇珠单抗的疗效相关生存曲线随时间相似。
- 安全性相关第1年粗生存函数:阿达木单抗0.91(95%CI 0.90-0.91),乌司奴单抗0.94(95%CI 0.94-0.95),司库奇尤单抗0.94(95%CI 0.92-0.94),古塞奇尤单抗0.96(95%CI 0.94-0.98),依奇珠单抗0.92(95%CI 0.89-0.94)。
- 安全性调整生存曲线:古塞奇尤单抗、乌司奴单抗和司库奇尤单抗相似;与乌司奴单抗相比,阿达木单抗(调整HR 1.66,95%CI 1.46-1.89)和依奇珠单抗(调整HR 1.52,95%CI 1.13-2.03)生存率更低。
关键数值与推荐
- 疗效相关第1年粗生存函数:阿达木单抗0.81(95%CI 0.80-0.82),乌司奴单抗0.89(95%CI 0.88-0.89),司库奇尤单抗0.86(95%CI 0.85-0.87),古塞奇尤单抗0.94(95%CI 0.92-0.96),依奇珠单抗0.86(95%CI 0.83-0.89)。
- 与乌司奴单抗相比,疗效调整HR:古塞奇尤单抗0.13(95%CI 0.03-0.56),阿达木单抗2.37(95%CI 2.03-2.76)。
- 安全性相关第1年粗生存函数:阿达木单抗0.91(95%CI 0.90-0.91),乌司奴单抗0.94(95%CI 0.94-0.95),司库奇尤单抗0.94(95%CI 0.92-0.94),古塞奇尤单抗0.96(95%CI 0.94-0.98),依奇珠单抗0.92(95%CI 0.89-0.94)。
- 与乌司奴单抗相比,安全性调整HR:阿达木单抗1.66(95%CI 1.46-1.89),依奇珠单抗1.52(95%CI 1.13-2.03)。
- 效应修饰因素包括银屑病关节炎、既往生物制剂暴露、甲受累和 ethnicity。
临床怎么用
- 作者认为,关于长期治疗持续性、安全性和耐受性的信息可能有助于患者及其临床医生做出启动生物制剂治疗的知情决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Drug survival of biologic therapies for psoriasis is a proxy for longer-term treatment effectiveness and safety. Patient factors that are associated with the survival of each biologic differently (effect modifiers) may inform the decision to choose between biologics. OBJECTIVE: To assess the drug survival associated with the effectiveness and safety of commonly used biologics for psoriasis in the UK and Ireland and identify effect modifiers for these biologics and their survival. DESIGN, SETTING, AND PARTICIPANTS: We conducted a prospective cohort study of patients with psoriasis using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) between November 2007 and August 2021. EXPOSURES: Adalimumab, ustekinumab, secukinumab, guselkumab, ixekizumab. MAIN OUTCOMES AND MEASURES: We conducted a survival analysis and fitted separate flexible parametric models for drug survival as a proxy for effectiveness and safety. RESULTS: A total of 16 122 treatment courses were included: 6607 (41.0%) in which treatment with adalimumab was initiated, 5405 (33.5%) with ustekinumab, 2677 (16.6%) with secukinumab, 730 (4.5%) with guselkumab, and 703 (4.4%) with ixekizumab. The crude survival functions at year 1 for measures of effectiveness for treatment with adalimumab was 0.81 (95% CI, 0.80-0.82), 0.89 for ustekinumab (95% CI, 0.88-0.89), 0.86 for secukinumab (95% CI, 0.85-0.87), 0.94 for guselkumab (95% CI, 0.92-0.96), and 0.86 for ixekizumab (95% CI, 0.83-0.89). The adjusted survival curves from the multivariable model for effectiveness showed that treatment with guselkumab had the higher survival (adjusted hazard ratio, 0.13; 95% CI, 0.03-0.56) and adalimumab had the lower survival (adjusted hazard ratio, 2.37; 95% CI, 2.03-2.76) compared with ustekinumab. Secukinumab and ixekizumab had similar survival curves over time. Psoriatic arthritis, previous biologic exposure, nail involvement, and ethnicity were effect modifiers for survival in association with treatment effectiveness. The crude survival functions at year 1 for safety were 0.91 for treatment with adalimumab (95% CI, 0.90-0.91), 0.94 for ustekinumab (95% CI, 0.94-0.95), 0.94 for secukinumab (95% CI, 0.92-0.94), 0.96 for guselkumab (95% CI, 0.94-0.98), and 0.92 for ixekizumab (95% CI, 0.89-0.94). Guselkumab, ustekinumab, and secukinumab had similar adjusted survival curves for safety, while adalimumab (adjusted hazard ratio, 1.66; 95% CI, 1.46-1.89) and ixekizumab (adjusted hazard ratio, 1.52; 95% CI, 1.13-2.03) had lower survival compared with ustekinumab. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that guselkumab had the highest drug survival in BADBIR of the included biologics for treatment persistence that was associated with effectiveness, and guselkumab had highest drug survival for safety compared with other biologics except ustekinumab. Psoriatic arthritis, nail involvement, previous biologic exposure, and ethnicity were effect modifiers for biologics and their survival in association with treatment effectiveness. This information on longer-term treatment persistence, safety, and tolerability may help patients and their clinicians make an informed decision to initiate treatment with a biologic therapy.
引用
- Yiu ZZN, Becher G, Kirby B, et al. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis. JAMA Dermatol. 2022. PMID: 35791876. doi:10.1001/jamadermatol.2022.2909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。